HRP20171121T8 - Metode za liječenje imunoloških poremećaja povezanih sa transplatacijom grafta sa solubilnim ctla4 mutiranim molekulama - Google Patents

Metode za liječenje imunoloških poremećaja povezanih sa transplatacijom grafta sa solubilnim ctla4 mutiranim molekulama

Info

Publication number
HRP20171121T8
HRP20171121T8 HRP20171121TT HRP20171121T HRP20171121T8 HR P20171121 T8 HRP20171121 T8 HR P20171121T8 HR P20171121T T HRP20171121T T HR P20171121TT HR P20171121 T HRP20171121 T HR P20171121T HR P20171121 T8 HRP20171121 T8 HR P20171121T8
Authority
HR
Croatia
Prior art keywords
muted
molecules
treatment
methods
disorders related
Prior art date
Application number
HRP20171121TT
Other languages
English (en)
Croatian (hr)
Inventor
David Hagerty
James Rusnak
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20171121T1 publication Critical patent/HRP20171121T1/hr
Publication of HRP20171121T8 publication Critical patent/HRP20171121T8/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HRP20171121TT 2005-04-06 2006-04-05 Metode za liječenje imunoloških poremećaja povezanih sa transplatacijom grafta sa solubilnim ctla4 mutiranim molekulama HRP20171121T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66877405P 2005-04-06 2005-04-06
PCT/US2006/012648 WO2006108035A1 (en) 2005-04-06 2006-04-05 Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
EP06749324.7A EP1868635B1 (en) 2005-04-06 2006-04-05 Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules

Publications (2)

Publication Number Publication Date
HRP20171121T1 HRP20171121T1 (hr) 2017-10-06
HRP20171121T8 true HRP20171121T8 (hr) 2017-11-03

Family

ID=36694299

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171121TT HRP20171121T8 (hr) 2005-04-06 2006-04-05 Metode za liječenje imunoloških poremećaja povezanih sa transplatacijom grafta sa solubilnim ctla4 mutiranim molekulama

Country Status (25)

Country Link
US (2) US7482327B2 (https=)
EP (1) EP1868635B1 (https=)
JP (1) JP2008535841A (https=)
KR (1) KR101235484B1 (https=)
CN (1) CN101198347A (https=)
AR (1) AR055052A1 (https=)
AU (1) AU2006231622B2 (https=)
BR (1) BRPI0608144A2 (https=)
CA (1) CA2603970A1 (https=)
CY (1) CY1119145T1 (https=)
DK (1) DK1868635T3 (https=)
EA (1) EA013122B1 (https=)
ES (1) ES2634260T3 (https=)
HR (1) HRP20171121T8 (https=)
IL (1) IL186189A (https=)
LT (1) LT1868635T (https=)
ME (1) ME02930B (https=)
MX (1) MX2007012222A (https=)
NO (1) NO342966B1 (https=)
NZ (2) NZ561655A (https=)
PL (1) PL1868635T3 (https=)
PT (1) PT1868635T (https=)
RS (1) RS56138B1 (https=)
SI (1) SI1868635T1 (https=)
WO (1) WO2006108035A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
JP2008535841A (ja) * 2005-04-06 2008-09-04 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
JP2012500855A (ja) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US9738872B2 (en) * 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
US20100297123A1 (en) * 2009-05-15 2010-11-25 Garrison Fathman C Combination therapy to inhibit t cell effector function
HUE030100T2 (en) * 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CN103282047B (zh) 2010-09-08 2016-08-24 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
JP2013540731A (ja) 2010-09-08 2013-11-07 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 安定かつ長期間の生着のための免疫抑制薬物組合せ
WO2013035099A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
SG11201506919XA (en) 2013-03-28 2015-10-29 Bristol Myers Squibb Co Methods for identifying patients at risk for costimulation blockade resistant rejection
CN104673822A (zh) * 2013-11-27 2015-06-03 深圳先进技术研究院 一种重组载体及其制备方法和应用
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
CN106132429A (zh) 2014-03-19 2016-11-16 百时美施贵宝公司 使用针对cd40l的域抗体治疗移植物排斥的方法
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN121159719A (zh) 2015-04-17 2025-12-19 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
EP3322424B1 (en) 2015-07-16 2023-10-11 Yeda Research and Development Co., Ltd. Use of anti third party central memory t cells
ES3064681T3 (en) 2017-01-18 2026-04-28 Yeda Res And Development Co Ltd Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
EP3809983B1 (en) 2018-06-22 2025-08-27 Mayo Foundation for Medical Education and Research Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality
WO2020010259A1 (en) * 2018-07-06 2020-01-09 Mayo Foundation For Medical Education And Research Methods and materials for improving transplant outcomes
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CN115089718B (zh) * 2021-11-30 2024-05-28 杭州瑞普晨创科技有限公司 用于异种移植的免疫抑制剂组合和免疫抑制方法
KR102929448B1 (ko) 2023-02-03 2026-02-26 이뮤노바이옴 주식회사 이식 거부 반응의 예방 또는 치료용 조성물
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
CA2580812A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7304033B2 (en) * 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
MXPA05006522A (es) 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP2008535841A (ja) * 2005-04-06 2008-09-04 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法

Also Published As

Publication number Publication date
IL186189A0 (en) 2008-01-20
PL1868635T3 (pl) 2017-10-31
NZ561655A (en) 2010-01-29
DK1868635T3 (en) 2017-09-11
LT1868635T (lt) 2017-07-10
IL186189A (en) 2015-11-30
HRP20171121T1 (hr) 2017-10-06
NO20075078L (no) 2008-01-04
BRPI0608144A2 (pt) 2009-11-17
AU2006231622A1 (en) 2006-10-12
NO342966B1 (no) 2018-09-10
CY1119145T1 (el) 2018-02-14
EA013122B1 (ru) 2010-02-26
EA200702180A1 (ru) 2008-10-30
AU2006231622B2 (en) 2012-07-05
KR20070119728A (ko) 2007-12-20
MX2007012222A (es) 2007-12-06
CA2603970A1 (en) 2006-10-12
EP1868635B1 (en) 2017-05-17
EP1868635A1 (en) 2007-12-26
SI1868635T1 (sl) 2017-07-31
NZ576434A (en) 2010-06-25
US20100041602A1 (en) 2010-02-18
US20070009511A1 (en) 2007-01-11
RS56138B1 (sr) 2017-10-31
US7482327B2 (en) 2009-01-27
PT1868635T (pt) 2017-07-27
AR055052A1 (es) 2007-08-01
JP2008535841A (ja) 2008-09-04
KR101235484B1 (ko) 2013-02-22
WO2006108035A1 (en) 2006-10-12
ME02930B (me) 2018-04-20
ES2634260T3 (es) 2017-09-27
CN101198347A (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
HRP20171121T8 (hr) Metode za liječenje imunoloških poremećaja povezanih sa transplatacijom grafta sa solubilnim ctla4 mutiranim molekulama
HUS2100015I1 (hu) Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
PL1951030T3 (pl) Udoskonalone sposoby i środki do wytwarzania hialuronianu
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
WO2007095638A3 (en) Boron-containing small molecules as anti-inflammatory agents
CR10679A (es) Novel anti-cd38 antibodies for the treatment of cancer
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
WO2009111676A3 (en) Boron-containing small molecules as anti-inflammatory agents
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DK1741768T4 (da) Fremgangsmåde til fremstilling af dieselcarbonhydrider
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
TW200740849A (en) Dual variable domain immunoglobulin and uses thereof
IL184734A0 (en) Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
EP2037961A4 (en) METHODS OF TREATING AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY
WO2007059203A3 (en) Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors
EP2010216A4 (en) MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
HUE042689T2 (hu) TGFbéta elleni antitestek
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
DK3199180T3 (da) Epha3-antistoffer til behandlingen af faste tumorer
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
EP1885402A4 (en) ANTIBODIES TO METAPNEUMOVIRUS OF MAMMALS
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
EP1993553A4 (en) METHOD FOR CANCER THERAPY AND STEM CELL MODULATION
EA201071221A1 (ru) Гетероциклические соединения
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα